Lantheus Holdings Inc (LNTH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lantheus Holdings Inc (LNTH) has a cash flow conversion efficiency ratio of 0.083x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($90.18 Million) by net assets ($1.09 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Lantheus Holdings Inc to measure how much of total assets are equity-financed.
Lantheus Holdings Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Lantheus Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check LNTH operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Lantheus Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lantheus Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arkema SA
PA:AKE
|
0.001x |
|
Sinotrans Ltd Class A
SHG:601598
|
0.043x |
|
Choice Hotels International Inc
NYSE:CHH
|
-0.169x |
|
Thai Airways International Public Company Limited
BK:THAI
|
0.005x |
|
Sonoco Products Company
NYSE:SON
|
-0.103x |
|
HUB24 Ltd
AU:HUB
|
0.156x |
|
West Fraser Timber Co Ltd
NYSE:WFG
|
-0.031x |
|
Macy’s Inc
NYSE:M
|
0.243x |
Annual Cash Flow Conversion Efficiency for Lantheus Holdings Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Lantheus Holdings Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Lantheus Holdings Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.09 Billion | $390.14 Million | 0.358x | -28.50% |
| 2024-12-31 | $1.09 Billion | $544.75 Million | 0.501x | +33.82% |
| 2023-12-31 | $815.89 Million | $305.26 Million | 0.374x | -40.63% |
| 2022-12-31 | $447.15 Million | $281.78 Million | 0.630x | +442.84% |
| 2021-12-31 | $464.44 Million | $53.92 Million | 0.116x | +264.07% |
| 2020-12-31 | $514.21 Million | $16.40 Million | 0.032x | -95.45% |
| 2019-12-31 | $114.60 Million | $80.38 Million | 0.701x | -18.61% |
| 2018-12-31 | $71.00 Million | $61.19 Million | 0.862x | -63.35% |
| 2017-12-31 | $23.29 Million | $54.78 Million | 2.352x | +604.63% |
| 2016-12-31 | $-106.52 Million | $49.64 Million | -0.466x | -296.81% |
| 2015-12-31 | $-185.29 Million | $21.76 Million | -0.117x | -142.47% |
| 2014-12-31 | $-239.27 Million | $11.59 Million | -0.048x | -173.26% |
| 2013-12-31 | $-235.52 Million | $-15.57 Million | 0.066x | +2976.73% |
| 2012-12-31 | $-173.10 Million | $-372.00K | 0.002x | -- |
About Lantheus Holdings Inc
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceut… Read more